معرفی
Olli-Pekka Kallioniemi is a Professor of Molecular Precision Medicine and Director of Science for Life Laboratory (SciLifeLab) at Karolinska Institutet. He leads the Precision Cancer Medicine research group within the Department of Oncology-Pathology, focusing on translational research to improve cancer treatment through ex vivo drug testing and multi-omics profiling. His work bridges laboratory discoveries with clinical applications, emphasizing actionable insights for personalized therapy.
Research Interests:
Dr. Kallioniemi’s group develops functional precision medicine approaches to identify therapeutic vulnerabilities in cancers like AML, ovarian, prostate, and renal cancers. Techniques include patient-derived 2D/3D cell models, organoids, and comprehensive genomic/drug-response profiling. Their work progresses through three translational phases: model feasibility (Phase I), representativity optimization (Phase II), and clinical actionability (Phase III).
Selected Achievements:
- Directed 75 million SEK in grants from the Swedish Cancer Society (2022)
- Pioneered functional drug testing platforms for solid tumors and hematologic malignancies
- Coordinated multi-institutional collaborations between Karolinska Institutet and the Institute for Molecular Medicine Finland
Labs/Teams:
His group operates at SciLifeLab (Stockholm) and the Institute for Molecular Medicine Finland (Helsinki), with sub-teams like the Functional Systems Oncology group led by Dr. Tom Erkers. Core personnel include postdoctoral researchers, PhD students, and clinical assistants.
